CPIX Cumberland Pharmaceuticals Inc

Price (delayed)

$2.28

Market cap

$33.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.51

Enterprise value

$34.72M

Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at ...

Highlights
The company's debt rose by 25% YoY but it fell by 6% QoQ
Cumberland Pharmaceuticals's gross profit has decreased by 5% YoY but it has increased by 3.4% QoQ
The net income has shrunk by 51% QoQ
Cumberland Pharmaceuticals's EPS has plunged by 50% from the previous quarter

Key stats

What are the main financial stats of CPIX
Market
Shares outstanding
14.66M
Market cap
$33.43M
Enterprise value
$34.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.85
Price to sales (P/S)
0.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.92
Earnings
Revenue
$37.87M
EBIT
-$7.29M
EBITDA
-$1.86M
Free cash flow
$3.64M
Per share
EPS
-$0.51
Free cash flow per share
$0.25
Book value per share
$2.67
Revenue per share
$2.58
TBVPS
$3.92
Balance sheet
Total assets
$92.52M
Total liabilities
$53.31M
Debt
$19.51M
Equity
$39.46M
Working capital
$19.5M
Liquidity
Debt to equity
0.49
Current ratio
1.8
Quick ratio
1.3
Net debt/EBITDA
-0.7
Margins
EBITDA margin
-4.9%
Gross margin
76.5%
Net margin
-20.1%
Operating margin
-23.9%
Efficiency
Return on assets
-8.4%
Return on equity
-17.9%
Return on invested capital
-21.2%
Return on capital employed
-10.7%
Return on sales
-19.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CPIX stock price

How has the Cumberland Pharmaceuticals stock price performed over time
Intraday
4.11%
1 week
-3.8%
1 month
1.79%
1 year
-21.92%
YTD
-51.18%
QTD
9.88%

Financial performance

How have Cumberland Pharmaceuticals's revenue and profit performed over time
Revenue
$37.87M
Gross profit
$28.97M
Operating income
-$9.06M
Net income
-$7.62M
Gross margin
76.5%
Net margin
-20.1%
The company's operating margin has shrunk by 98% YoY
CPIX's operating income has dropped by 92% year-on-year and by 4.8% since the previous quarter
The net income has shrunk by 51% QoQ
The company's net margin fell by 46% QoQ

Growth

What is Cumberland Pharmaceuticals's growth rate over time

Valuation

What is Cumberland Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.85
P/S
0.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.92
Cumberland Pharmaceuticals's EPS has plunged by 50% from the previous quarter
CPIX's P/B is 41% below its 5-year quarterly average of 1.4 and 25% below its last 4 quarters average of 1.1
CPIX's equity is down by 18% year-on-year and by 3.8% since the previous quarter
The stock's price to sales (P/S) is 60% less than its 5-year quarterly average of 2.1 and 29% less than its last 4 quarters average of 1.2
The revenue has grown by 3.4% from the previous quarter but it has contracted by 3.2% YoY

Efficiency

How efficient is Cumberland Pharmaceuticals business performance
The company's return on equity has shrunk by 58% QoQ
CPIX's return on invested capital is down by 49% since the previous quarter
The ROA has contracted by 47% from the previous quarter
Cumberland Pharmaceuticals's ROS has decreased by 45% from the previous quarter

Dividends

What is CPIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPIX.

Financial health

How did Cumberland Pharmaceuticals financials performed over time
The total assets is 74% greater than the total liabilities
The quick ratio has decreased by 30% YoY
The company's total liabilities rose by 30% YoY but it fell by 4.6% QoQ
The company's debt is 51% lower than its equity
The debt to equity has soared by 53% YoY but it has contracted by 3.9% from the previous quarter
The company's debt rose by 25% YoY but it fell by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.